An Outtier

Leuven, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Needle or Drip?-Real-World Comparison of Intravenous to Subcutaneous Infliximab and Vedolizumab in the Management of Inflammatory Bowel Diseases.

Needle or Drip?-Real-World Comparison of Intravenous to Subcutaneous Infliximab and Vedolizumab in the Management of Inflammatory Bowel Diseases.

Journal: Digestive diseases and sciences

Published: October 28, 2024

Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank Analysis.

Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank Analysis.

Journal: United European gastroenterology journal

Published: July 26, 2024

Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials.

Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials.

Journal: Journal of Crohn's & colitis

Published: March 02, 2024

Efficacy and Safety of Ustekinumab for Chronic Pouchitis: A Prospective Open-label Multicenter Study.

Efficacy and Safety of Ustekinumab for Chronic Pouchitis: A Prospective Open-label Multicenter Study.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: February 01, 2024

Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD.

Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD.

Journal: Journal of Crohn's & colitis

Published: October 21, 2023

Screening Failure in a Large Clinical Trial Centre for Inflammatory Bowel Diseases: Rates, Causes, and Outcomes.

Screening Failure in a Large Clinical Trial Centre for Inflammatory Bowel Diseases: Rates, Causes, and Outcomes.

Journal: Inflammatory bowel diseases

Published: July 06, 2022

Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases.

Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases.

Journal: CPT: pharmacometrics & systems pharmacology

Published: April 08, 2022

Microbiome variance of the small bowel in Crohn's disease.

Microbiome variance of the small bowel in Crohn's disease.

Journal: Gut

Published: March 07, 2022

Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.

Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.

Journal: Alimentary pharmacology & therapeutics

Published: February 12, 2022

Using provocative design to foster electronic informed consent innovation.

Using provocative design to foster electronic informed consent innovation.

Journal: BMC medical informatics and decision making

Published: December 17, 2021

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study.

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study.

Journal: United European gastroenterology journal

Published: July 28, 2021

Chronic Antibiotic-Refractory Pouchitis: Management Challenges.

Chronic Antibiotic-Refractory Pouchitis: Management Challenges.

Journal: Clinical and experimental gastroenterology

Published: February 01, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026